Home » Business » Astrazeneca, one seventh of Pfizer’s revenues from vaccines. The group has decided not to aim for profits with the ongoing pandemic

Astrazeneca, one seventh of Pfizer’s revenues from vaccines. The group has decided not to aim for profits with the ongoing pandemic


AstraZeneca closes the first half of the year with a 23% increase in revenues a 15.5 billion dollars (13 billion euros) and a + 31% in the second quarter alone. This is what we read in a note from the group. Come on Covid vaccines, the Anglo-Swedish pharmaceutical brand has collected 1.1 billion euros in the first half of 2021, about one-seventh of Pfizer, which just raised its full-year revenue estimates. Excluding this contribution, Astrazeneca explains, the revenues are increased by 14% in the semester. For the future, the group sees further development also thanks to the recent acquisition of Alexion Pharma. The results released today are slightly lower than expected of analysts, after the disclosure of the data, the stock of the group fluctuates on the stock market around parity.

Vaccine revenues could rise with the green light for doses from the United States. However, the company warns that there may be delays on this front, due to the decision to resort to the ordinary procedure and not the urgent one. Mene Pangalos, AstraZeneca’s vice president, said US regulators required an astounding amount of data to initiate the practice.

Astrazeneca, whose vaccine developed with the University of Oxford (using a technology other than Pfizer’s or Moderna mRna) is on the market at lower prices compared to the doses of the US Pfizer and Moderna, it has sold so far 1 billion doses. Unlike other pharmaceutical companies, Astrazeneca has agreed to sell the vaccine without aiming for profits while the pandemic is ongoing. “It won’t last forever,” explained the CEO Pascal Soriot adding that “sooner or later the profits on the vaccine will have to be there even if we do not intend to make big profits on this product. However, we will continue to charge different prices depending on the economic conditions of the countries to which we sell the ampoules “.

Support ilfattoquotidiano.it: your contribution is essential

Your support helps us ensure our independence and allows us to continue producing quality online journalism that is open to all, without paywalls. Your contribution is essential for our future.
Become a supporter too

Thank you,
Peter Gomez

ilFattoquotidiano.it

Support now

Payments available

Next article

Unicredit officially opens the practice to acquire the “good part” of Mps. The dreaded “stew” is expected for the Tuscan bank

next

Leave a Comment